You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 11, 2025

CLINICAL TRIALS PROFILE FOR SAXAGLIPTIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SAXAGLIPTIN HYDROCHLORIDE

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00316082 ↗ Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise Completed AstraZeneca Phase 3 2006-06-01 The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise
NCT00313313 ↗ A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas Completed AstraZeneca Phase 3 2006-04-01 The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
NCT00295633 ↗ A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone Completed AstraZeneca Phase 3 2006-03-01 The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone
NCT00121667 ↗ Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone Completed AstraZeneca Phase 3 2005-08-01 The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone
NCT00121641 ↗ Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise Completed AstraZeneca Phase 3 2005-07-01 The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 5 of 5 entries

Clinical Trial Conditions for SAXAGLIPTIN HYDROCHLORIDE

Condition Name

3530176005101520253035Type 2 Diabetes MellitusType 2 DiabetesDiabetes Mellitus, Type 2Diabetes[disabled in preview]
Condition Name for SAXAGLIPTIN HYDROCHLORIDE
Intervention Trials
Type 2 Diabetes Mellitus 35
Type 2 Diabetes 30
Diabetes Mellitus, Type 2 17
Diabetes 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

938700102030405060708090100Diabetes Mellitus, Type 2Diabetes MellitusGlucose IntoleranceDiabetes Mellitus, Type 1[disabled in preview]
Condition MeSH for SAXAGLIPTIN HYDROCHLORIDE
Intervention Trials
Diabetes Mellitus, Type 2 93
Diabetes Mellitus 87
Glucose Intolerance 5
Diabetes Mellitus, Type 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SAXAGLIPTIN HYDROCHLORIDE

Trials by Country

+
Trials by Country for SAXAGLIPTIN HYDROCHLORIDE
Location Trials
United States 490
Canada 80
Mexico 69
China 65
India 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for SAXAGLIPTIN HYDROCHLORIDE
Location Trials
Texas 35
California 28
Florida 23
Ohio 20
Georgia 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SAXAGLIPTIN HYDROCHLORIDE

Clinical Trial Phase

36.1%38.9%24.1%0051015202530354045Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for SAXAGLIPTIN HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 39
Phase 3 42
Phase 2/Phase 3 1
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

72.7%15.7%6.6%00102030405060708090CompletedUnknown statusRecruiting[disabled in preview]
Clinical Trial Status for SAXAGLIPTIN HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 88
Unknown status 19
Recruiting 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SAXAGLIPTIN HYDROCHLORIDE

Sponsor Name

trials010203040506070AstraZenecaBristol-Myers SquibbCanadian Network for Observational Drug Effect Studies, CNODES[disabled in preview]
Sponsor Name for SAXAGLIPTIN HYDROCHLORIDE
Sponsor Trials
AstraZeneca 72
Bristol-Myers Squibb 17
Canadian Network for Observational Drug Effect Studies, CNODES 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

49.2%49.2%00102030405060708090100IndustryOtherNIH[disabled in preview]
Sponsor Type for SAXAGLIPTIN HYDROCHLORIDE
Sponsor Trials
Industry 96
Other 96
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

SAXAGLIPTIN HYDROCHLORIDE Market Analysis and Financial Projection

Saxagliptin Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction to Saxagliptin Hydrochloride

Saxagliptin hydrochloride, commonly known by its brand name Onglyza, is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. It works by increasing the levels of incretin hormones, which in turn enhance insulin production and reduce glucagon levels, helping to lower blood sugar levels[5].

Clinical Trials Update

Mechanism of Action and Efficacy

Clinical trials have consistently demonstrated the efficacy of saxagliptin in improving glycemic control in patients with type 2 diabetes. A Phase 3 study conducted by AstraZeneca involved subjects receiving saxagliptin in combination with metformin. The study aimed to assess whether saxagliptin could improve the body's ability to produce its own insulin and lower blood glucose levels. The trial included a randomized, double-blind design with subjects receiving either saxagliptin or a placebo, along with metformin as needed for rescue therapy[3].

Ongoing and Completed Trials

  • CV181-041 Study: This clinical trial evaluated the efficacy and safety of saxagliptin in combination with metformin compared to metformin alone or a placebo. The study involved 156 subjects aged 18-70 years and was conducted over a period of up to 104 weeks. The primary purpose was to assess the pharmacodynamic effects of saxagliptin in treating type 2 diabetes[3].

Safety and Adverse Effects

Clinical trials have also highlighted the safety profile of saxagliptin. Common adverse effects reported include upper respiratory tract infections, urinary tract infections, and headaches. However, saxagliptin has been shown to have a favorable safety profile with minimal systemic side effects due to its selective inhibition of the DPP-4 enzyme[5].

Market Analysis

Market Size and Growth

The saxagliptin market is projected to grow significantly over the forecast period. According to IndustryARC, the market size is estimated to reach $255 million by 2027, growing at a Compound Annual Growth Rate (CAGR) of 4.17% from 2022 to 2027[2].

Market Segmentation

By Dosage

The market is segmented into 2.5 mg and 5 mg tablets. The 5 mg segment is expected to grow with the fastest CAGR of 4.8% during the forecast period due to the increasing use of Onglyza 5 mg film-coated tablets[2].

By Age Group

The market is segmented into adult and geriatric populations. The geriatric segment is significant due to the higher prevalence of type 2 diabetes among older adults[2].

By Distribution Channel

The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies held the largest market share in 2021, driven by the convenience and increased use during the COVID-19 pandemic. However, hospital pharmacies are expected to grow with the fastest CAGR of 4.9% as life returns to pre-pandemic normalcy[2].

By Geography

Geographically, the market is segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America accounted for the highest revenue share in 2021 and is expected to continue dominating the market. The Asia-Pacific region, however, is projected to have the fastest CAGR due to the growing population and increasing healthcare spending in countries like India and China[2].

Market Drivers

Increasing Prevalence of Diabetes

The rising incidence of type 2 diabetes, driven by factors such as changing lifestyles, reduced physical exercise, and high obesity rates, is a significant driver of the saxagliptin market. Saxagliptin's role in managing blood sugar levels by enhancing insulin production and reducing glucagon levels makes it a valuable treatment option[2][4].

Government Financing and Healthcare Spending

Increased government financing for healthcare and the growing spending on diabetes treatments are also driving the market growth. Innovative R&D activities in diabetes therapeutics further propel the market[2][4].

Market Restraints

Adverse Effects and Regulatory Framework

Despite its benefits, saxagliptin is associated with adverse effects such as upper respiratory tract infections, urinary tract infections, and headaches. Additionally, a strict regulatory framework for diabetic drugs can restrain market growth[2][4].

Patent Issues

The approval of generic versions of saxagliptin, such as the one by Sun Pharmaceutical Industries, is often delayed due to patent issues. For instance, the tentative approval of Sun Pharmaceutical's ANDA for saxagliptin and metformin hydrochloride extended-release tablets was delayed due to patent expirations in 2023 and 2025[1].

Key Players

The saxagliptin market is dominated by key players such as Bristol-Myers Squibb Company and AstraZeneca plc. These companies have been instrumental in the development, marketing, and distribution of saxagliptin under various brand names like Onglyza and Kombiglyze[4].

Regional Insights

North America

North America holds the largest market share due to the high prevalence of type 2 diabetes and the increasing use of screening tests like oral glucose tolerance tests. The region's sedentary lifestyle and high intake of junk food also contribute to the growing demand for saxagliptin[2].

Asia-Pacific

The Asia-Pacific region is expected to grow at the fastest CAGR due to the expanding population, particularly in countries like India and China, and the increasing healthcare spending in the region[2].

Future Projections

Market Growth

The saxagliptin market is expected to continue growing driven by the increasing prevalence of type 2 diabetes, innovative R&D activities, and the expanding healthcare spending in emerging economies.

Emerging Trends

The use of online pharmacies is expected to continue growing, driven by convenience and the ease of access to medications. Hospital pharmacies are also expected to see significant growth as normalcy returns post-pandemic[2].

Key Takeaways

  • Clinical Efficacy: Saxagliptin has been shown to be effective in improving glycemic control in patients with type 2 diabetes.
  • Market Growth: The market is projected to reach $255 million by 2027, growing at a CAGR of 4.17%.
  • Distribution Channels: Online pharmacies currently dominate, but hospital pharmacies are expected to grow rapidly.
  • Geographical Dominance: North America leads the market, but the Asia-Pacific region is expected to grow the fastest.
  • Adverse Effects: Common adverse effects include upper respiratory tract infections, urinary tract infections, and headaches.

FAQs

What is saxagliptin used for?

Saxagliptin is used for the management of type 2 diabetes mellitus. It works by inhibiting the DPP-4 enzyme, which helps in lowering blood sugar levels[5].

What are the common adverse effects of saxagliptin?

Common adverse effects include upper respiratory tract infections, urinary tract infections, and headaches[5].

Which regions dominate the saxagliptin market?

North America currently dominates the market, but the Asia-Pacific region is expected to grow at the fastest CAGR[2].

What are the key drivers of the saxagliptin market?

The increasing prevalence of type 2 diabetes, innovative R&D activities, and growing healthcare spending are key drivers of the market[2][4].

Who are the major players in the saxagliptin market?

Major players include Bristol-Myers Squibb Company and AstraZeneca plc[4].

Sources

  1. FDA Approval Letter: Saxagliptin and Metformin Hydrochloride Extended-Release Tablets[1].
  2. IndustryARC Report: Saxagliptin Market Forecast (2022-2027)[2].
  3. AstraZeneca Clinical Trials: Study assessing Saxagliptin treatment in subjects with type 2 diabetes[3].
  4. Allied Market Research: Saxagliptin Market Size, Share and Trends[4].
  5. DrugBank: Saxagliptin: Uses, Interactions, Mechanism of Action[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.